Join us on Wednesday, March 1^st for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Wednesday, March 1, 2023
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Module 1: Optimizing the Use of Hormonal Therapy in Prostate Cancer Management
• Module 2: Evidence-Based Application of Other Therapeutic Approaches

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appraise published research findings and current guideline recommendations on optimal management approaches for patients with biochemical recurrence following local treatment for prostate cancer, and counsel appropriate patients regarding the potential benefits of systemic therapy.
• Evaluate published research supporting the FDA approvals of secondary hormonal agents for the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into current clinical management algorithms.
• Establish an evidence-based approach to the selection and sequencing of available therapeutic options for metastatic CRPC (mCRPC), considering patient age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
• Assess the available research supporting the use of PARP inhibitor monotherapy for patients with mCRPC harboring a homologous recombination repair (HRR) gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
• Develop an understanding of the rationale for, available and emerging data with and ongoing research efforts evaluating PARP inhibitors in combination with androgen receptor-targeted therapy, and consider the potential role of these novel regimens for patients both with and without HHR gene mutations.
• Appreciate available Phase III data documenting the efficacy of PSMA-targeted radioligand therapy in patients with progressive PSMA-positive mCRPC, and consider the current clinical role of this strategy.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Dorff — Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Pfizer Inc. Dr Sartor — Advisory Committee: Advanced Accelerator Applications, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clarity Pharmaceuticals, Constellation Pharmaceuticals, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Sanofi; Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, ARTbio, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Convergent Therapeutics Inc, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Foundation Medicine, Fusion Pharmaceuticals, Genzyme Corporation, Hengrui Therapeutics Inc, ITM Isotopen Technologien München AG, Janssen Biotech Inc, Merck, Morphimmune, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Northstar, Novartis, Noxopharm, Pfizer Inc, POINT Biopharma, Progenics Pharmaceuticals Inc, Sanofi, TeneoBio, Telix Pharmaceuticals Limited, Tessa Therapeutics, Theragnostics; Contracted Research: Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Invitae, Janssen Biotech Inc, Lantheus, Merck, Novartis, Progenics Pharmaceuticals Inc, TeneoBio; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Myovant Sciences Pfizer Inc; Stock Options/Ownership — Public Company: AbbVie Inc, Cardinal Health, Clarity Pharmaceuticals, Clovis Oncology, GSK, Lilly, United Health Group; Nonrelevant Financial Relationship: NRG Oncology — Co-Chairman of GU Committee, Ratio Therapeutics — Stock ownership.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.